ResearcherDankook UniversityNo recent work listed
Yong Weon Yi
Matched on ORCID iD 0000-0001-6895-0465; OpenAlex author ID A5018057046.
Their work
- Papers
- 6 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Collaborators
- 6
2012: 1 paper · 2013: 1 paper · 2014: 2 papers · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper
Papers 6
- Doxycycline potentiates the anti-proliferation effects of gemcitabine in pancreatic cancer cells. First author PMID 34354858↗
- Comparative analysis of NRF2-responsive gene expression in AcPC-1 pancreatic cancer cell line. First author DOI 10.1007/s13258-014-0253-2↗
- Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine. Co-author DOI 10.3892/ijo.2013.2229↗
- Combination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant pancreatic cancer MIA PaCa-2 cells. Co-author DOI 10.3892/ijo.2014.2357↗
- Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine. Co-author DOI 10.1111/jcmm.12101↗
- Exploring protein kinase inhibitors: potentiating gemcitabine efficacy in pancreatic cancer. Co-author DOI 10.1097/mpa.0b013e318230f71a↗
Closest collaborators
The 6 strongest of 6 ranked by shared papers, trials and grants, with recent and small-team work weighing most.
- Yeon-Sun Seong · 5 shared papers, 2012–2021
- Paper Doxycycline potentiates the anti-proliferation effects of gemcitabine in pancreatic cancer cells. PMID 34354858↗
- Paper Combination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant … DOI 10.3892/ijo.2014.2357↗
- Paper Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine. DOI 10.3892/ijo.2013.2229↗
- Young Bin Hong · 4 shared papers, 2012–2021
- Paper Doxycycline potentiates the anti-proliferation effects of gemcitabine in pancreatic cancer cells. PMID 34354858↗
- Paper Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine. DOI 10.3892/ijo.2013.2229↗
- Paper Exploring protein kinase inhibitors: potentiating gemcitabine efficacy in pancreatic cancer. DOI 10.1097/mpa.0b013e318230f71a↗
- Insoo Bae · 4 shared papers, 2012–2014
- Paper Combination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant … DOI 10.3892/ijo.2014.2357↗
- Paper Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine. DOI 10.3892/ijo.2013.2229↗
- Paper Exploring protein kinase inhibitors: potentiating gemcitabine efficacy in pancreatic cancer. DOI 10.1097/mpa.0b013e318230f71a↗
- Hong-Quan Duong · 3 shared papers, 2013–2014
- Paper Combination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant … DOI 10.3892/ijo.2014.2357↗
- Paper Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine. DOI 10.3892/ijo.2013.2229↗
- Paper Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine. DOI 10.1111/jcmm.12101↗
- Seunghoon Oh · 1 shared paper, 2015
- Yeon Jeong Kim · 1 shared paper, 2013
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.